Mirvetuximab Soravtansin beim platinresistenten Ovarialkarzinom

Title	Journal	Journal Categories	Citations	Publication Date
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study				2023

[email protected]

The content of this site is for informational purposes only, and the website is not responsible for the accuracy of the information provided.